SecBot SecBot
SECBOTREPLAY Home › Report › DNTH

DNTH · Dianthus Therapeutics raised approximately $719 million in gross…

Dianthus Therapeutics, Inc. · PRESS-RELEASE filed Mar 12, 2026 at 16:01 ET

At the news

NEUTRALIMPACT 6/10

PRESS-RELEASE filed Mar 12, 2026 at 16:01 ET

Dianthus Therapeutics raised approximately $719 million in gross proceeds through a public offering of 8.47 million common shares and pre-funded warrants for 402,468 additional shares, priced at $81.00 per share. The capital will fund clinical development, commercial readiness, and general corporate purposes, extending the company's runway but increasing potential dilution for existing shareholders.

  • Closed public offering of 8,470,989 common shares and pre-funded warrants for 402,468 shares
  • Offering price: $81.00 per share; pre-funded warrants priced at $80.999 with $0.001 exercise price
  • Aggregate gross proceeds: ~$719 million before expenses
  • Proceeds to fund clinical and preclinical programs, commercial readiness, and general corporate use

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access